blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3365269

EP3365269 - CRISPR-CAS9 DELIVERY TO HARD-TO-TRANSFECT CELLS VIA MEMBRANE DEFORMATION [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  17.07.2020
Database last updated on 30.09.2024
FormerRequest for examination was made
Status updated on  27.07.2018
FormerThe international publication has been made
Status updated on  28.04.2017
Most recent event   Tooltip17.07.2020Application deemed to be withdrawnpublished on 19.08.2020  [2020/34]
Applicant(s)For all designated states
The Methodist Hospital
6565 Fannin Street, MS D200
Houston, Texas 77030 / US
[2018/35]
Inventor(s)01 / QIN, Lidong
3215 Blue Bonnet Boulevard
Houston, TX 77025 / US
02 / HAN, Xin
4045 Linkwood Drive
Apt 216
Houston, TX 77025 / US
03 / LIU, Zongbin
2250 Holly Hall Street
Apt 2102
Houston, TX 77054 / US
04 / MA, Yuan
7675 Phoenix Drive
Apt 303
Houston, TX 77030 / US
05 / ZHANG, Kai
6565 Fannin Street
MS-D200
Houston, TX 77030 / US
 [2018/35]
Representative(s)Küchler, Stefan
Stefan T. Küchler
Patentanwalt
Färberstraße 20
90402 Nürnberg / DE
[N/P]
Former [2018/35]Küchler, Stefan
Patentanwalt
Färberstrasse 20
90402 Nürnberg / DE
Application number, filing date16858105.619.10.2016
[2018/35]
WO2016US57639
Priority number, dateUS201562243275P19.10.2015         Original published format: US 201562243275 P
US201562252337P06.11.2015         Original published format: US 201562252337 P
[2018/35]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017070169
Date:27.04.2017
Language:EN
[2017/17]
Type: A1 Application with search report 
No.:EP3365269
Date:29.08.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 27.04.2017 takes the place of the publication of the European patent application.
[2018/35]
Search report(s)International search report - published on:US27.04.2017
(Supplementary) European search report - dispatched on:EP22.05.2019
ClassificationIPC:B81B1/00, C12M1/00, C12N15/87, C12M1/42, B01L3/00, C12N15/90
[2019/25]
CPC:
C12M35/04 (EP,US); B01L3/50273 (US); B01L3/502746 (US);
C12N15/87 (EP,US); C12N15/907 (EP,US); B01L2200/0636 (US);
B01L2200/0663 (US); B01L2200/10 (US); C12N2310/20 (US) (-)
Former IPC [2018/35]B81B1/00, C12M1/00, C12N15/87
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/35]
TitleGerman:CRISPR-CAS9-ABGABE AN SCHWER ZU TRANSFIZIERENDE ZELLEN DURCH MEMBRANVERFORMUNG[2018/35]
English:CRISPR-CAS9 DELIVERY TO HARD-TO-TRANSFECT CELLS VIA MEMBRANE DEFORMATION[2018/35]
French:DISTRIBUTION, PAR DÉFORMATION MEMBRANAIRE, DE CRISPR-CAS9 À DES CELLULES DIFFICILES À TRANSFECTER[2018/35]
Entry into regional phase18.05.2018National basic fee paid 
18.05.2018Search fee paid 
18.05.2018Designation fee(s) paid 
18.05.2018Examination fee paid 
Examination procedure18.05.2018Examination requested  [2018/35]
18.05.2018Date on which the examining division has become responsible
11.02.2019Amendment by applicant (claims and/or description)
18.12.2019Application deemed to be withdrawn, date of legal effect  [2020/34]
30.01.2020Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2020/34]
Fees paidRenewal fee
30.10.2018Renewal fee patent year 03
Penalty fee
Additional fee for renewal fee
31.10.201904   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]WO2013059343  (MASSACHUSETTS INST TECHNOLOGY [US], et al) [A] 1-15 * the whole document * * pages 28-29 * * page 17, line 20 - line 26; claim 11 * * page 6, line 18 - line 19 *;
 [A]WO2015023982  (MASSACHUSETTS INST TECHNOLOGY [US]) [A] 1-15 * the whole document *;
 [A]WO2015061458  (CELLANYX DIAGNOSTICS INC [US]) [A] 1-15 * the whole document *;
 [XDI]  - X. HAN ET AL, "CRISPR-Cas9 delivery to hard-to-transfect cells via membrane deformation", SCIENCE ADVANCES, (20150814), vol. 1, no. 7, doi:10.1126/sciadv.1500454, pages e1500454 - e1500454, XP055339291 [XD] 1-5,7-15 * the whole document * * page 3, column 8; figure 1 * * page 3, column 2 * * page 2, column 1 * [I] 6

DOI:   http://dx.doi.org/10.1126/sciadv.1500454
 [XI]  - XIN HAN ET AL, "Supplementary material for: CRISPR-Cas9 delivery to hard-to-transfect cells via membrane deformation", SCIENCE ADVANCES, (20150801), vol. 1, no. 7, doi:10.1126/sciadv.1500454, page e1500454, XP055587982 [X] 1-5,7-15 * the whole document * [I] 6

DOI:   http://dx.doi.org/10.1126/sciadv.1500454
 [A]  - A. SHAREI ET AL, "A vector-free microfluidic platform for intracellular delivery", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, US, (20130122), vol. 110, no. 6, doi:10.1073/pnas.1218705110, ISSN 0027-8424, pages 2082 - 2087, XP055551255 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1073/pnas.1218705110
 [A]  - ARMON SHAREI ET AL, "Cell Squeezing as a Robust, Microfluidic Intracellular Delivery Platform", JOURNAL OF VISUALIZED EXPERIMENTS, (20131107), no. 81, doi:10.3791/50980, XP055182930 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.3791/50980
International search[Y]WO2015023982  (MASSACHUSETTS INST TECHNOLOGY [US]) [Y] 26, 65 * Especially para [0005], [0022], [0023] *;
 [Y]WO2015061458  (CELLANYX DIAGNOSTICS INC [US]) [Y] 33, 69* Especially para [0012], [0016], [0069], Fig 2 *;
 [XY]  - HAN et al., "CRISPR-Cas9 delivery to hard-to-transfect cells via membrane deformation.", Sci Adv., vol. 1, no. 7, (20150814), pages 1 - 8, URL: http://advances.sciencemag.org/highwire/filestream/186449/field_highwire_adjunct_files/0/1500454_SM.pdf, XP055339291 [X] 1-25, 27-32, 34-64, 66-68 * Especially abstract, pg 1 col 2 para 1, pg 2 col 1 para 1, pg 2 col 1 para 2 - pg 2 col 2 para 1, pg 4 col 1 para 1, pg 6 col 2 para 2, pg 7 col 1 para 2, pg 7 col 1 para 3, Fig 1A, Fig 1B, Fig 1C, Fig S1A * [Y] 26, 33, 65, 69

DOI:   http://dx.doi.org/10.1126/sciadv.1500454
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.